Viking Global Investors
AMLX icon

Viking Global Investors’s Amylyx Pharmaceuticals AMLX Stock Holding History

Viking Global Investors’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-2,962,555
Closed -$43.6M – 84
2023
Q4 		$43.6M Hold
2,962,555
– – 0.16% 68
2023
Q3 		$54.2M Hold
2,962,555
– – 0.22% 65
2023
Q2 		$63.9M Hold
2,962,555
– – 0.26% 70
2023
Q1 		$86.9M Sell
2,962,555
-1,672,051
-36% -$58.1M 0.41% 46
2022
Q4 		$171M Sell
4,634,606
-1,135,930
-20% -$40.3M 0.86% 37
2022
Q3 		$162M Sell
5,770,536
-1,400,000
-20% -$34.9M 0.75% 39
2022
Q2 		$138M Hold
7,170,536
– – 0.63% 47
2022
Q1 		$92.1M Buy
+7,170,536
New +$162M 0.37% 65

Other funds holding AMLX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Viking Global Investors's AMLX Position: Q1 2024 in Review

Viking Global Investors sold out of Amylyx Pharmaceuticals (AMLX) in Q1 2024, closing a stake of 2,962,555 shares — an estimated $43.6M sold.

Viking Global Investors first reported a position in AMLX in Q1 2022 and held it in 8 quarters. The position peaked at $171M in Q4 2022. 143 funds tracked by Wall St. Rank hold AMLX as of Q1 2024.

  • Viking Global Investors reported no remaining Amylyx Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Viking Global Investors sold 2,962,555 Amylyx Pharmaceuticals shares in Q1 2024, an estimated $43.6M.
  • Viking Global Investors first reported a position in Amylyx Pharmaceuticals in Q1 2022 and held it in 8 quarters.
  • Viking Global Investors's Amylyx Pharmaceuticals position peaked at $171M in Q4 2022.
  • 143 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q1 2024.

Based on Viking Global Investors's 13F filing for Q1 2024, filed 15 May 2024.